Study design
This is a pre-planned exploratory analysis of a phase IIIb, open-label, multicenter, randomized, three-arm study aimed to evaluate the non-inferiority of two DEX-sparing regimens when combined with oral NEPA versus the guideline-consistent DEX regimen in patients receiving cisplatin-containing chemotherapy